InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,431.60
(
-0.04%
)
US TECH 100
19,168.00
(
0.52%
)
Dow Jones
38,589.16
(
-0.15%
)
Brent Oil
82.28
(
0.00%
)
Bitcoin
66,505.11
(
0.47%
)
Post# of 252202
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

jellybean

Send PM Follow Ignore
Followers 10
Posts 1097
Boards Moderated 0
Alias Born 08/23/2004

jellybean

Re: Praveen post# 164592

Monday, 07/29/2013 5:10:49 PM

Monday, July 29, 2013 5:10:49 PM

Post# of 252202
Yes, CC-292 obtained from their purchase of Avila. http://www.celgene.com/pdfs/2011_ASH_AVL-292.pdf

Like Ibrutinib, the drug covalently attaches to C481 of the BTK binding pocket and has an IC50 of <0.5 nm, so highly specific. The drug has very low affinity for other kinases with cysteine in their binding pockets. On paper, the two drugs look very similar.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up